Osterweis Capital Management Inc Kodiak Sciences Inc. Transaction History

Osterweis Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $785,394 - $9.91 Million	-110,775 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$80.85 - $128.49 $80,850 - $128,490	-1,000 Reduced 0.89%	110,775 $9.39 Million
Q3 2021 Nov 15, 2021	SELL	$81.97 - $106.94 $163,940 - $213,880	-2,000 Reduced 1.76%	111,775 $10.7 Million
Q2 2021 Aug 16, 2021	SELL	$77.2 - $126.54 $1.13 Million - $1.85 Million	-14,634 Reduced 11.4%	113,775 $10.6 Million
Q1 2021 May 14, 2021	SELL	$110.45 - $164.47 $481,451 - $716,924	-4,359 Reduced 3.28%	128,409 $14.6 Million
Q4 2019 Feb 14, 2020	SELL	$13.9 - $76.65 $1.11 Million - $6.11 Million	-79,702 Reduced 37.51%	132,768 $9.55 Million
Q2 2019 Aug 14, 2019	SELL	$6.2 - $12.0 $711,406 - $1.38 Million	-114,743 Reduced 35.07%	212,470 $2.49 Million
Q1 2019 May 15, 2019	BUY	$6.43 - $9.44 $17,361 - $25,488	2,700 Added 0.83%	327,213 $2.14 Million
Q4 2018 Feb 14, 2019	BUY	$6.11 - $10.43 $1.98 Million - $3.38 Million	324,513 New	324,513 $2.31 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $417M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Osterweis Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Osterweis Capital Management Inc with notifications on news.